Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-01-15

Clinical Trial Update: R230C and C230C Variants of ABCA1 and Glyburide Response [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the impact of ABCA1 R230C and C230C genetic variants on glyburide response in individuals with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Glyburide (glyburide)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED